Pharmaceuticals, Biotechnology and Life Sciences
Abivax kicked off book-building and the filing of an amended registration statement on Form F-1, to issue approximately 20,325,500 ordinary shares
Abivax has treated the first patient in its Phase 2b/3 study of ABX464 in COVID-19 patients at the University Hospital Center in Nice, France (CHU Nice) in a randomized, double-blind, placebo-controlled study, to see the the effects of early treatment in 1034 Covid-19 older or high-risk patients.
Abivax said Monday that the German regulatory authority for drugs and medical products, BfArM (Bundesinstitut für Arnzeimittel und Medizinprodukte), has approved its Phase 2b/3 study of ABX464 in COVID-19 patients.
Abivax said Thursday that ABX464 inhibits replication of SARS-CoV-2 in an in vitro reconstituted human respiratory epithelium model, as assessed by Transepithelial electrical resistance and RTqPCR.
Abivax has doest the first patient with an iNKT agonist, ABX196, in a Phase 1/2 study to evaluate safety, tolerability and preliminary efficacy of the combination therapy. ABX196 is Abivax’s second compound in clinical development, following its lead candidate ABX464 in inflammatory diseases.
Abivax, a biotechnology company targeting the immune system to eliminate viral diseases, has recently discovered several molecules that are active against the virus in vitro, some of which could be developed as therapeutic drug-candidates against dengue fever.
Abivax said on Tuesday it would receive €8.4 million from “Projets de R&D Structurants Pour la Compétitivité” (PSPC) of the “Invest in the Future Program” (PIA).
ABIVAX has appointed Didier Blondel as Chief Financial Officer, effective January 2nd, 2017.
ABIVAX is hosting an R&D Day at the Company’s new collaborative laboratory with the French National Center for Scientific Research (CNRS) in Montpellier.